
- Pharmaceutical Commerce - September/October 2016
Generics distributor Anda, Inc. has a new owner: Teva Pharma
Deal deepens Teva’s business in generics
Having acquired nearly all of Allergan’s generics business in a $40.5-billion blockbuster deal that was announced last year and closed on Aug. 2, Teva Pharma then announced the acquisition of Anda, Inc., an Allergan subsidiary that is the fourth-largest distributor of generic drugs in the US. Purchase price was $500 million; Anda’s 2016 revenue was projected to be $1.5 billion, and to add $0.15 to Teva’s earnings per share.
Anda distributes generic, brand, specialty and OTC pharma products from more than 300 manufacturers to retail independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics and physician offices across the United States, according to an Allergan statement. The company is headquartered in Weston, FL, and operates a distribution center from there as well as from Groveport, OH and Olive Branch, MS.
The deal further cements Allergan’s transformation into an innovator pharma company, which had changed when Actavis Pharma, a major generics producer, merged with the company in 2014 in a $66-billion deal (which also thwarted a competing bid from Valeant Pharma—dodged a bullet there, as
Save
Articles in this issue
about 9 years ago
Cold Chain Global Forum is coming upabout 9 years ago
5 CAPA best practices for clinical researchabout 9 years ago
Integrating patient training into product launchesabout 9 years ago
Value frameworks are here: What to do about them?about 9 years ago
Orphan drug commercialization is maturingabout 9 years ago
Advancing the biopharma cold chainabout 9 years ago
A conversation with Gerry Gleeson, Walgreens Specialty Pharmacyabout 9 years ago
Since 1841: The Story of an Enduring Family BusinessNewsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.





